Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus COXANTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus COXANTO.
CHILDREN'S IBUPROFEN vs COXANTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
1 g intravenous every 6 hours.
None Documented
None Documented
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category D/X
Category C
NSAID
NSAID